PresentationOperator Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to the BridgeBio Pharma Limb-Girdle Muscular Dystrophy Type 2i/R9 FORTIFY Phase III Interim Analysis Results Webinar. [Operator Instructions] Thank you. I would now like to turn the conference over to Dr. Neil Kumar, Chief Executive Officer. Dr. Kumar, please go ahead. ...

Company Performance Summary - Horizon Space Acquisition I Corp. (HSPOR) experienced a price drop to $0.12, a decline of around 41.77%, indicating challenges in achieving its business objectives [2][7] - Lixiang Education Holding Co., Ltd. (LXEH) saw its price fall to $0.94, a dramatic decrease of 66.71%, although it has regained compliance with Nasdaq's market value requirements [3][7] - Skye Bioscience, Inc. (SKYE) experienced a decrease in its stock price to $1.89, a drop of 60.20%, following disappointing topline data from its Phase 2a clinical trial [4] - Stellar V Capital Corp. Warrant (SVCCW) saw its warrant price adjust to $0.34, reflecting a decrease of 35.85%, indicating uncertainty about its future acquisition prospects [5] Market Trends and Reactions - The companies mentioned span various industries, including healthcare, education, and financial services, and have experienced significant market adjustments [6] - The reasons behind these price movements could include broader market trends, industry-specific challenges, or company-related developments, with investors closely monitoring for signs of recovery [6]

Core Viewpoint - Nektar Therapeutics Inc. (NKTR) stock experienced a significant increase despite the absence of company-specific news, likely influenced by the negative performance of Sanofi SA following the COAST 1 trial results [1] Group 1: Trial Results and Comparisons - The COAST 1 trial demonstrated that amlitelimab met all primary and key secondary endpoints, showing statistically significant skin clearance and disease severity improvement compared to placebo at Week 24 for patients aged 12 years and older with moderate-to-severe atopic dermatitis [2] - Although the trial met its endpoints, the benefit magnitude of amlitelimab was below investor expectations when compared to Phase 2 benchmarks and approved treatments like Dupixent [3] - On the EASI-75 score, amlitelimab showed a 20% improvement over placebo, significantly lower than the 39% improvement reported in the previous Phase 2b study [4] Group 2: Other Relevant Studies - Nektar's ongoing Phase 2b REZOLVE-AD study of rezpegaldesleukin showed statistically significant data, with patients experiencing a 53% to 61% improvement in symptoms after 16 weeks, compared to a 31% improvement in the placebo group [4] - At week 16, a high dose of 24 µg/kg q2w achieved statistical significance on EASI-90, indicating a substantial reduction in disease severity [5] Group 3: Stock Performance - NKTR stock rose by 24.27%, reaching $35.48 during the last trading session [5]

Investment Rating - The industry view is rated as Attractive [7] Core Insights - The report highlights over 70 oral presentations from Chinese scholars at the 2025 ASCO, including 11 late-breaking abstracts, showcasing advancements in various pharmaceutical developments [1] - Sino Biopharma's combination of Benmelstobart (PD-L1) with anlotinib showed superior efficacy in first-line squamous non-small cell lung cancer (sq-NSCLC) with a median progression-free survival (mPFS) of 10.12 months compared to 7.79 months for tislelizumab [2] - CSPC's SYS6010 (EGFR ADC) demonstrated preliminary efficacy in advanced gastrointestinal cancers with mPFS of 5.8 months in gastric cancer patients [3] - Kelun Pharma's sac-TMT (TROP2 ADC) achieved a confirmed overall response rate (ORR) of 59.3% in first-line non-squamous NSCLC [4] - Fosun Pharma's HLX43 (PD-L1 ADC) showed an ORR of 31.3% in late-line solid tumors, with competitive results in NSCLC patients [5] Company Summaries Sino Biopharma - The combination therapy of Benmelstobart and anlotinib is expected to release Phase 3 data for first-line NSCLC and maintenance treatment after radiochemotherapy soon [2] - TQB2102 (HER2 bsAbADC) achieved an ORR of 53.4% in late-line HER2 low-expressing breast cancer [2] CSPC - SYS6010 in combination with SYH2051 showed preliminary efficacy for second-line advanced gastrointestinal cancers, with a G3+ treatment-related adverse event (TRAE) rate of 48% [3] - ALMB-0168 (Cx43 agonist) for relapsed/refractory osteosarcoma showed an ORR of 20% and a disease control rate (DCR) of 90% [10] Kelun Pharma - Sac-TMT demonstrated a 70.7% ORR and a mPFS of 13.4 months in first-line triple-negative breast cancer (TNBC) [11] - In the third-line EGFR-mutant NSCLC setting, sac-TMT achieved a PFS of 6.9 months compared to 2.8 months for docetaxel [11] Fosun Pharma - HLX43's competitive ORR of 38.1% in NSCLC patients during the dose-expansion phase indicates potential for further development [5]